Abstract:Currently available preventive therapies for breast cancer (BC) are primarily based on selective estrogen receptor (ER) modulators (SERMs) to target ER signaling. However, these drugs only partially prevent ER-positive BCs (EPBCs) but not ER-negative BCs (ENBCs), rendering approximately 60% of BCs unpreventable. About half of established EPBCs respond to SERMs and aromatase inhibitors (AIs), whereas ENBCs, most of which are triple-negative BCs (TNBCs), do not respond to SERMs or AIs. To date, there is no other targeted therapy for ENBCs or nonresponsive/resistant EPBCs, presenting a pressing need of non-ER-based targets and the agents that can effectively target such targets. Dysregulated glucose and energy metabolism is critically involved in the development and progression of various cancers, however, such a role in BC development remains largely unknown, thus representing a key knowledge gap and a potential avenue for non-ER-based targeted prevention and treatment of BC. Several metabolic and biogenetic anticancer therapies have been developed, but none has progressed to clinical use owing to their limited potency or specificity and/or their undesirable drug properties, such as toxicity and poor bioavailability. We recently developed a new class of anticancer agents, including HJC0152, that target glucose and energy metabolism and thus may have promise for the prevention and treatment of BCs, particularly ENBCs and resistant EPBCs. In this study, orally active HJC0152 differentially modulates glycolytic enzymes in BC cells. HJC0152 also regulates the transcription of genes involved in glucose and mitochondrial energy metabolism, including the subunits of mitochondrial respiratory chain complexes. HJC0152 also significantly inhibits Complexes IV but increases Complex V (ATP synthase) function, while Complexes I and II function is minimally affected. Migration and invasion of MDA-MB-231 cells are significantly inhibited by HJC0152 exposure. In vivo , HJC0152 significantly blocked mammary tumor development in mouse ENBC and TNBC models via inhibiting premalignant lesions. HJC0152 also dramatically blocked the development of experimental lung macro- and micro-metastasis in mice. These results suggest that HJC0152 can reprogram/restore the dysregulated glucose metabolism by inducing specific glycolytic enzyme expression and mitochondrial respiratory chain function, likely via targeting one or more upstream signal molecule(s) that regulates glucose and energy metabolism, thereby suppressing BC development and progression. To elucidate the mechanisms and discover the oncogenic drivers that promote BC development and progression, we are employing several strategies including in silico HJC0152 function-modelling and structure-modelling analysis, Unique Polymer Technology, and HJC0152-derived tool compounds to identify the HJC0152-interacting target(s). An initial in silico analysis has resulted in 12 potential targets, including the known JAK/STAT pathway molecules and proteins important for glucose/energy metabolism for further validation studies. This work was supported by Grants P50 CA097007, and P30DA028821(JZ) from NIH, CPRIT (JZ), John Sealy Memorial Endowment Fund (JZ), DFI Seed Grants from MDACC (QS), the Prevent Cancer Foundation (QS), and the PREVENT Program from NIH/NCI (QS). Citation Format: Jiabin Dong, Dengfeng Li, Hyejin Kim, Hong Wang, Zhi Zheng, Ziwei Zhang, Na Ye, Haiying Chen, Jia Zhou, Qiang Shen. Glucose metabolism modulator HJC0152 differentially regulates glycolytic enzymes to suppress breast carcinogenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-299. doi:10.1158/1538-7445.AM2017-LB-299

Modulation of the activities of AMP‐activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2‐deoxyglucose

AMPK-dependent Phosphorylation of the GATOR2 Component WDR24 Suppresses Glucose-Mediated Mtorc1 Activation.

Inhibition of Mtorc1 Signaling Sensitizes Hepatocellular Carcinoma Cells to Glycolytic Stress

Synergistic Effects Between Mtor Complex 1/2 and Glycolysis Inhibitors on Non-Small Cell Lung Carcinoma Metabolism.

The Role of AMPK in Regulation of the Insulin Signal Transduction Pathway

Targeting AMPK for cancer prevention and treatment.

Synergistic Effects Between Mtor Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells

The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.

The activation of the p53 pathway by the AMP mimetic AICAR is reduced by inhibitors of the ATM or mTOR kinases

The mixed blessing of AMPK signaling in Cancer treatments

2-Deoxy-d-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth

Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells

AMP-activated Protein Kinase α2 Protects against Liver Injury from Metastasized Tumors via Reduced Glucose Deprivation-induced Oxidative Stress

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich’s Ascites Tumor in Mice

Role of AMP-activated protein kinase in cancer therapy

Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy

mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress

Glucose Metabolism Modulator Hjc0152 Differentially Regulates Glycolytic Enzymes To Suppress Breast Carcinogenesis

Activation of AMPK by Metformin Promotes Renal Cancer Cell Proliferation under Glucose Deprivation Through Its Interaction with PKM2